Increased CDRH Post-Approval Vigilance Plays Out In Medtronic X-Stop Trials
This article was originally published in The Gray Sheet
Executive Summary
Medtronic clinical executive Ruchir Sehra says CDRH's newfound rigor in the postmarket area is evident in its approach to the firm's post-approval study of the X-Stop spinal implant